The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1103-1109, November 2007

The effect of corticosteroids on the disposal of long-acting β2-agonists by airway smooth muscle cells

  • Gabor Horvath, MD, PhD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of Miami Miller School of Medicine, Miami, Fla
    • Department of Pulmonology, Semmelweis University School of Medicine, Budapest, Hungary
    • Corresponding Author InformationReprint requests: Adam Wanner, MD, and Gabor Horvath, MD, PhD, Division of Pulmonary and Critical Care Medicine, University of Miami Miller School of Medicine, P.O. Box 016960 (R-47), Miami, FL 33101.
  • ,
  • Eliana S. Mendes, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of Miami Miller School of Medicine, Miami, Fla
  • ,
  • Nathalie Schmid, BSc

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of Miami Miller School of Medicine, Miami, Fla
  • ,
  • Andreas Schmid, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of Miami Miller School of Medicine, Miami, Fla
  • ,
  • Gregory E. Conner, PhD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of Miami Miller School of Medicine, Miami, Fla
  • ,
  • Matthias Salathe, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of Miami Miller School of Medicine, Miami, Fla
  • ,
  • Adam Wanner, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of Miami Miller School of Medicine, Miami, Fla
    • Corresponding Author InformationReprint requests: Adam Wanner, MD, and Gabor Horvath, MD, PhD, Division of Pulmonary and Critical Care Medicine, University of Miami Miller School of Medicine, P.O. Box 016960 (R-47), Miami, FL 33101.

Received 25 January 2007; received in revised form 19 July 2007; accepted 7 August 2007. published online 08 October 2007.

Background

Organic cation transporters (OCTs) have an important role in tissue distribution and elimination of cationic drugs. Carrier-mediated disposal of cationic bronchodilators in the airway tissue, however, is incompletely understood.

Objectives

We sought to assess the uptake of long-acting β2-agonist bronchodilators by bronchial and vascular smooth muscle cells.

Methods

Human airway cells and tissues obtained from organ donors were evaluated for cationic drug transporter expression by means of quantitative RT-PCR and immunofluorescence. For in vitro functional studies, tritiated formoterol and tritiated salmeterol uptake by bronchial and vascular smooth muscle cells was measured.

Results

Quantitative RT-PCR analysis revealed high mRNA levels for the corticosteroid-sensitive OCT3 in bronchial and vascular smooth muscle cells. Immunofluorescence staining of airway sections confirmed OCT3 expression in these cells. In bronchial smooth muscle cells, uptake of the cationic formoterol was inhibited with OCT inhibitors. Corticosteroids also inhibited formoterol uptake through a rapid (within 15 minutes) nongenomic action, with the following rank order for inhibitory potency: corticosterone > budesonide > fluticasone. The corticosteroid-induced inhibition was significantly higher in vascular than bronchial smooth muscle cells. In comparison with formoterol, uptake of the noncharged lipophilic salmeterol was approximately 10-fold higher and insensitive to all OCT inhibitors and corticosteroids.

Conclusions

Our findings suggest that corticosteroids, through OCT3 inhibition, rapidly interfere with the disposal of cationic drugs by smooth muscle cells in the airway.

Clinical implications

This novel immediate interaction between corticosteroids and cationic β2-agonist bronchodilators supports the use of such combinations in the pharmacotherapy of asthma.

Key words: Bronchial smooth muscle, organic cation transporter, corticosteroids, budesonide, fluticasone, nongenomic, long-acting β2-agonists, formoterol, salmeterol

Abbreviations used: DEC22, 1,1′-Diethyl-2,2′-cyanine, IC50, Inhibitory concentration of 50%, MPP+, N-methyl-4-phenylpyridinium, OCT, Organic cation transporter, OCTN, Organic cation/carnitine transporter, TEA+, Tetraethylammonium

 

 Supported in part by an academic research grant from AstraZeneca and National Heart, Lung, and Blood Institute grants HL-60644 and HL-66125. G.H. is a recipient of the Bolyai Fellowship of the Hungarian Academy of Sciences.

 Disclosure of potential conflict of interest: A. Wanner has received grant support from AstraZeneca. The other authors have declared that they have no conflict of interest.

PII: S0091-6749(07)01629-6

doi:10.1016/j.jaci.2007.08.034

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1103-1109, November 2007